» Articles » PMID: 28072597

Reperfusion Injury in ST-segment Elevation Myocardial Infarction: the Final Frontier

Overview
Date 2017 Jan 11
PMID 28072597
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

ST-segment elevation myocardial infarction is a major cause of morbidity and mortality worldwide. Reperfusion injury (RI) following the opening of an occluded coronary artery mitigates the effect of reperfusion by further accentuating ischemic damage and increasing infarct size. Experimental studies have shown that nearly 50% of final infarct size is attributable to RI, an elusive phenomenon that remains resistant to treatment. This review proposes a hypothesis to explain the failure of strategies that have been used in an attempt to prevent RI. This hypothesis suggests that, after a certain duration of myocardial ischemia in the affected myocardium, three phases of myocardial damage occur: reversible ischemia, irreversible ischemia, and necrosis. In the reversible ischemia phase, cellular adaptive responses remain functional, and cellular repair and thus recovery of cellular functions is possible, whereas in the irreversible ischemia phase protective maneuvers fail to confer cytoprotection. Preventive therapies for RI fail because they cannot prevent cell death once cells have entered the irreversible ischemia phase, although they may succeed in postponing cell death. Failure to salvage myocardium with irreversible ischemia in addition to postponement and change in the mode of cell death (mainly from necrosis to apoptosis) by various RI preventive strategies may be the key to understanding the failure of these strategies in the clinical setting, despite their success in the reduction of infarct size in the experimental setting. Early reperfusion before large amounts of myocardium at risk reach the stage of irreversible ischemia is the best strategy for reduction of RI-related myocardial damage.

Citing Articles

Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy.

Ndrepepa G, Kastrati A J Clin Med. 2023; 12(17).

PMID: 37685660 PMC: 10488607. DOI: 10.3390/jcm12175592.


SENP2-mediated SERCA2a deSUMOylation increases calcium overload in cardiomyocytes to aggravate myocardial ischemia/reperfusion injury.

Luo Y, Zhou S, Xu T, Wu W, Shang P, Wang S Chin Med J (Engl). 2023; 136(20):2496-2507.

PMID: 37462038 PMC: 10586866. DOI: 10.1097/CM9.0000000000002757.


Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms.

Zhu P, Shen J, Qian R, Xu J, Liu C, Hu W Front Pharmacol. 2023; 14:1165212.

PMID: 37261285 PMC: 10228700. DOI: 10.3389/fphar.2023.1165212.


Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention.

Kang S, Meng X, Li J Pak J Med Sci. 2022; 38(1):9-15.

PMID: 35035393 PMC: 8713218. DOI: 10.12669/pjms.38.1.4413.


microRNA-130a-5p suppresses myocardial ischemia reperfusion injury by downregulating the HMGB2/NF-κB axis.

Li Y, Zhang H, Li Z, Yan X, Li Y, Liu S BMC Cardiovasc Disord. 2021; 21(1):121.

PMID: 33658008 PMC: 7931544. DOI: 10.1186/s12872-020-01742-4.